Xtrackers MSCI World Health Care UCITS ETF 1C GBP is a equity ETF from Xtrackers tracking the MSCI World Health Care index through physical replication. Domiciled in Ireland and launched in 2016, the fund manages about 3.2 bn € and charges a TER of 0.25% — 25 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Xtrackers MSCI World Health Care UCITS ETF 1C GBP competes with 1 other products on the same index (MSCI World Health Care): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.25% against a group median of 0.28%. It has been listed since 2016, 10 years of track record.
On a €10,000 investment the TER costs 25 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 48.6% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in GBP. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| Eli Lilly and Company | 11.8% |
| Johnson & Johnson | 7.5% |
| AbbVie Inc | 5.5% |
| UnitedHealth Group Incorporated | 4.6% |
| Merck & Company Inc | 3.9% |
| Roche Holding AG | 3.6% |
| Novartis AG | 3.5% |
| AstraZeneca PLC | 3.5% |
| Amgen Inc | 2.4% |
| Thermo Fisher Scientific Inc | 2.3% |
| Borsa Italiana | XDWH | EUR |
| XETRA | XDWH | EUR |
| Francoforte | XDWH | EUR |
| London Stock Exchange | XDWH | USD |
| London Stock Exchange | XWHS | GBP |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.